Prima BioMed's CAN-002 CVac(TM) Trial Published in Journal for ImmunoTherapy of Cancer
June 23, 2014 08:51 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jun 23, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company") today announced that a research article titled "A phase 2, single-arm study of...
Prima BioMed to Present at 2014 WAGO Annual Meeting
June 19, 2014 08:19 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jun 19, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company") today advised that the Western Association of Gynecologic Oncologists (WAGO)...
CVAC Demonstrates Positive Trend in Overall Survival in Second Remission Ovarian Cancer
June 01, 2014 19:38 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jun 1, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
Interim overall survival data from CAN-003 clinical trial demonstrates...
Prima Biomed to Host Conference Call to Discuss Abstract Presented at ASCO on New Interim Overall Survival and Final Progression Free Survival Data for the Company's CAN-003 Trial
May 30, 2014 08:16 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - May 30, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company") today advised that the Company will host a conference call and webcast...
Prima's CVac Patent Application Receives U.S. Notice of Allowance
May 25, 2014 21:21 ET
|
Prima Biomed
SYDNEY, AUSTRALIA--(Marketwired - May 25, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") is pleased to announce that the Company has received a Notice of Allowance from...
Prima BioMed's CVac Demonstrates Improvement in Progression-Free Survival in Second Remission Ovarian Cancer
May 14, 2014 18:00 ET
|
Prima Biomed Ltd.
SYDNEY, AUSTRALIA--(Marketwired - May 14, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
Final PFS data from CAN-003 trial of CVac indicate stronger trends toward...
Prima BioMed's CVac(TM) Granted Fast Track Designation by FDA
May 09, 2014 07:00 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - May 9, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima") is pleased to announce today that the United States Food and Drug Administration ("FDA")...
Prima BioMed Third Quarter Conference Call
April 29, 2014 09:52 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Apr 29, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") today released its Appendix 4C - Quarterly Report for...
Prima BioMed's CAN-004 Phase 2 Trial for CVac(TM) Commences Recruitment
April 28, 2014 09:31 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Apr 28, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima") today announced that enrolment has commenced for its amended phase 2 CAN-004 clinical trial in...
Prima BioMed to Present at 13th Annual Needham Healthcare Conference
April 06, 2014 21:30 ET
|
Prima BioMed
SYDNEY, AUSTRALIA--(Marketwired - Apr 6, 2014) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company") today announced that its Chief Executive Officer, Matthew Lehman, will present...